Test helps target glioblastoma patients most likely to benefit from bevacizumab
A new test may help identify newly diagnosed glioblastoma patients more
likely to benefit from bevacizumab (Avastin®), according to new research
from The University of Texas MD Anderson Cancer Center.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news